Background:
Cysteinyl-leukotrienes
are mediators of
inflammatory
responses in
bronchial asthma. We
studied the genes
encoding the enzymes
involved in their
synthesis to
identify risk
factors for asthma.
The promoter
polymorphisms LTC4S
444 A/C, ALOX5
176/147, and
ALOX5AP 169/146
have been reported
to be associated
with bronchial
asthma.
Methods: We
analyzed the effects
of LTC4S 444 A/C,
ALOX5 176/147, and
ALOX5AP 169/146 on
asthma
susceptibility by
means of a
case-control study
with 193 ethnically
matched, unrelated
individuals.
Participants were
classified as severe
asthmatics,
nonsevere
asthmatics, and
nonasthmatics, using
a combination of 2
techniques:
polymerase chain
reaction-restricted
fragment length
polymorphism and
multiplex capillary
electrophoresis.
Results: No
association was
found between these
polymorphisms and
asthma, neither
individually nor in
combination.
Conclusion:
Although the studied
polymorphisms have
been previously
reported to
constitute risk
factors for the
disease, we found no
association between
LTC4S 444 A/C,
ALOX5 176/147, and
ALOX5AP 169/146
polymorphisms and
bronchial asthma.
Key words:
Bronchial asthma.
5-Lipoxygenase
pathway. Promoter.
Polymorphism. Risk.
|